IL139164A - Riluzole and levodopa combinations for treating parkinson's disease - Google Patents

Riluzole and levodopa combinations for treating parkinson's disease

Info

Publication number
IL139164A
IL139164A IL13916499A IL13916499A IL139164A IL 139164 A IL139164 A IL 139164A IL 13916499 A IL13916499 A IL 13916499A IL 13916499 A IL13916499 A IL 13916499A IL 139164 A IL139164 A IL 139164A
Authority
IL
Israel
Prior art keywords
riluzole
disease
treating parkinson
levodopa
combinations
Prior art date
Application number
IL13916499A
Other languages
English (en)
Other versions
IL139164A0 (en
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of IL139164A0 publication Critical patent/IL139164A0/xx
Publication of IL139164A publication Critical patent/IL139164A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
IL13916499A 1998-04-24 1999-04-22 Riluzole and levodopa combinations for treating parkinson's disease IL139164A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9805153A FR2777781B1 (fr) 1998-04-24 1998-04-24 Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
PCT/FR1999/000953 WO1999055336A1 (fr) 1998-04-24 1999-04-22 Associations de riluzole et de levodopa pour le traitement de la maladie de parkinson

Publications (2)

Publication Number Publication Date
IL139164A0 IL139164A0 (en) 2001-11-25
IL139164A true IL139164A (en) 2005-12-18

Family

ID=9525640

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13916499A IL139164A (en) 1998-04-24 1999-04-22 Riluzole and levodopa combinations for treating parkinson's disease

Country Status (22)

Country Link
US (1) US6387936B1 (cs)
EP (1) EP1071422B1 (cs)
JP (1) JP2002512963A (cs)
KR (1) KR100597170B1 (cs)
AT (1) ATE386520T1 (cs)
AU (1) AU768069B2 (cs)
CA (1) CA2329636C (cs)
CY (1) CY1110448T1 (cs)
CZ (1) CZ300825B6 (cs)
DE (1) DE69938179T2 (cs)
DK (1) DK1071422T3 (cs)
ES (1) ES2300141T3 (cs)
FR (1) FR2777781B1 (cs)
HU (1) HU228902B1 (cs)
IL (1) IL139164A (cs)
NO (1) NO329032B1 (cs)
PT (1) PT1071422E (cs)
RU (1) RU2225204C2 (cs)
SK (1) SK285531B6 (cs)
UA (1) UA70319C2 (cs)
WO (1) WO1999055336A1 (cs)
ZA (1) ZA200005758B (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786101B1 (fr) * 1998-11-24 2002-07-05 Aventis Laboratoire Utilisation de la nicergoline dans le traitement de la spasticite
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
GB0007193D0 (en) * 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
US7585627B2 (en) * 2004-05-21 2009-09-08 Duke University Polymorphism in tryptophan hydroxylase-2 controls brain serotonin synthesis
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
JP5112876B2 (ja) * 2004-11-07 2013-01-09 エフ． ギルフォード ティモシー 還元型グルタチオン経口投与のためのリポソーム処方物
GB0504103D0 (en) * 2005-02-28 2005-04-06 Syngenta Ltd Novel method
CA2613631A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008003028A2 (en) * 2006-06-28 2008-01-03 Chelsea Therapeutics, Inc. Pharmaceutical compositions comprising droxidopa
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
ES2500053T3 (es) * 2007-03-09 2014-09-29 Chelsea Therapeutics, Inc. Composición farmacéutica que comprende droxidopa para el tratamiento de la fibromialgia
JP2010526820A (ja) * 2007-05-07 2010-08-05 チェルシー・セラピューティクス，インコーポレイテッド 気分障害、睡眠障害、または注意欠陥障害を治療するドロキシドパおよびその医薬組成物
MX2010014222A (es) * 2008-06-30 2011-03-29 Novartis Ag Star Combinaciones que comprenden moduladores de mglur para el tratamiento de enfermedad de parkinson.
WO2010054273A1 (en) * 2008-11-06 2010-05-14 Synosia Therapeutics Treatment of restless leg syndrome and sleep disorders
EP2228054A1 (en) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
EP2629615B1 (en) 2010-10-22 2018-10-10 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
RU2057529C1 (ru) * 1994-05-30 1996-04-10 Алексей Михайлович Коршунов Способ лечения синдрома паркинсонизма

Also Published As

Publication number Publication date
AU768069B2 (en) 2003-12-04
ATE386520T1 (de) 2008-03-15
US6387936B1 (en) 2002-05-14
SK15882000A3 (sk) 2001-04-09
NO20005290D0 (no) 2000-10-20
NO20005290L (no) 2000-10-20
UA70319C2 (en) 2004-10-15
IL139164A0 (en) 2001-11-25
ES2300141T3 (es) 2008-06-01
SK285531B6 (sk) 2007-03-01
DE69938179D1 (de) 2008-04-03
HUP0101645A3 (en) 2002-10-28
DE69938179T2 (de) 2009-02-12
CZ20003908A3 (cs) 2001-02-14
CZ300825B6 (cs) 2009-08-19
KR100597170B1 (ko) 2006-07-05
JP2002512963A (ja) 2002-05-08
EP1071422A1 (fr) 2001-01-31
CA2329636A1 (fr) 1999-11-04
KR20010042960A (ko) 2001-05-25
HU228902B1 (en) 2013-06-28
DK1071422T3 (da) 2008-06-16
CA2329636C (fr) 2009-09-08
WO1999055336A1 (fr) 1999-11-04
FR2777781A1 (fr) 1999-10-29
RU2225204C2 (ru) 2004-03-10
PT1071422E (pt) 2008-05-05
ZA200005758B (en) 2002-01-17
EP1071422B1 (fr) 2008-02-20
HUP0101645A2 (hu) 2001-09-28
AU3425599A (en) 1999-11-16
CY1110448T1 (el) 2015-04-29
NO329032B1 (no) 2010-08-02
FR2777781B1 (fr) 2004-04-09

Similar Documents

Publication Publication Date Title
IL139164A (en) Riluzole and levodopa combinations for treating parkinson's disease
IL108845A0 (en) Use of anticonvulsants in the treatment of neuro-aids
MX9704377A (es) Uso de pramipexole como agente neuroprotector.
GB0108592D0 (en) Therapeutic agents
PL346904A1 (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
BG104038A (en) Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
AP9200355A0 (en) "Therapeutic agent"
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
ZA99740B (en) Application of 2-amino-6-trifluoromethoxybenzothiazole for the prevention or treatment of cerebellar dysfunction.
HUP9904029A3 (en) Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis
GB9922194D0 (en) Compounds for improved treatment of parkinson's disease
AU7419501A (en) Use of riluzole or its salts for preventing and treating adrenoleukodystrophy
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
AU6955294A (en) Agents for the prevention and treatment of parkinson's disease
AU2002318888A1 (en) Metal Chelators for use in the treatment of Alzheimer's Disease
ZA997090B (en) "A composition for the treatment of wood".
ZA200102029B (en) Pharmaceutical agents for the treatment of Parkinson's disease, ADHD and microadenomas.
ZA200005847B (en) Cabergoline and pramipexole for treating CNS diseases, especially Parkinson's Disease.
SI1076559T1 (sl) Kabergolin in pramipeksol za zdravljenje bolezni centralnega zivcnega sistema, posebno Parkinsonove bolezni
SI1007040T1 (en) Use of phanquinone for the treatment of alzheimer's disease
AU6331199A (en) Oxazolidine derivatives for the treatment and prevention of metabolic bone disorders

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees